JP2023547883A5 - - Google Patents

Info

Publication number
JP2023547883A5
JP2023547883A5 JP2023525008A JP2023525008A JP2023547883A5 JP 2023547883 A5 JP2023547883 A5 JP 2023547883A5 JP 2023525008 A JP2023525008 A JP 2023525008A JP 2023525008 A JP2023525008 A JP 2023525008A JP 2023547883 A5 JP2023547883 A5 JP 2023547883A5
Authority
JP
Japan
Prior art keywords
csf
item
recombinant human
cells
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547883A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/056413 external-priority patent/WO2022093671A1/en
Publication of JP2023547883A publication Critical patent/JP2023547883A/ja
Publication of JP2023547883A5 publication Critical patent/JP2023547883A5/ja
Pending legal-status Critical Current

Links

JP2023525008A 2020-10-26 2021-10-25 顆粒球マクロファージコロニー刺激因子変異体 Pending JP2023547883A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105425P 2020-10-26 2020-10-26
US63/105,425 2020-10-26
US202163177481P 2021-04-21 2021-04-21
US63/177,481 2021-04-21
PCT/US2021/056413 WO2022093671A1 (en) 2020-10-26 2021-10-25 Granulocyte macrophage-colony stimulating factor mutants

Publications (2)

Publication Number Publication Date
JP2023547883A JP2023547883A (ja) 2023-11-14
JP2023547883A5 true JP2023547883A5 (enExample) 2024-11-06

Family

ID=81383210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525008A Pending JP2023547883A (ja) 2020-10-26 2021-10-25 顆粒球マクロファージコロニー刺激因子変異体

Country Status (5)

Country Link
US (1) US20240182535A1 (enExample)
EP (1) EP4232067A4 (enExample)
JP (1) JP2023547883A (enExample)
CA (1) CA3196431A1 (enExample)
WO (1) WO2022093671A1 (enExample)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5032676A (en) * 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
EP0276846A3 (en) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
AU1369088A (en) * 1987-02-06 1988-08-24 Genetics Institute Inc. Colony stimulating factors having reduced levels of carbohydrate
JPH03502322A (ja) * 1987-10-30 1991-05-30 イミュネックス・コーポレーション ヒトコロニー形成刺激因子の非グリコシル化類似体
JPH02152995A (ja) * 1988-07-08 1990-06-12 Sumitomo Chem Co Ltd ヒト顆粒球・マクロファージコロニー刺激因子の分離精製法
ATE210182T1 (de) * 1993-06-30 2001-12-15 Lucky Ltd Modifizierte-granulocyte-makrophage-kolonie- stimulierender-faktor-gen und seine expression in hefe
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US20080076706A1 (en) * 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US20040091995A1 (en) * 2001-06-15 2004-05-13 Jeffrey Schlom Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2006079169A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
US9320777B2 (en) * 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure

Similar Documents

Publication Publication Date Title
JP6499592B2 (ja) Ｂ型肝炎ワクチン
Silin et al. Synthetic and natural immunomodulators acting as interferon inducers
US20120045445A1 (en) Method of treating viral diseases
KR20010030563A (ko) 인터페론 칸센서스 및 인터루킨-1 수용체 길항물질을 포함하는 다발성경화증을 치료하기 위한 제약학적 조성물
USRE40882E1 (en) Antiviral nasal drops comprising recombinant interferon a biocompatible polymer and an antioxidant
RU2003104525A (ru) Применение штаммов вируса parapox ovis для получения антивирусных и противораковых лекарственных средств
Huang et al. Protective effects of recombinant human granulocyte macrophage colony stimulating factor on H1N1 influenza virus-induced pneumonia in mice
JP2022513438A5 (enExample)
Balsari et al. Natural antibodies to IL-2
CN112843092B (zh) 免疫细胞在治疗疾病中的应用及其制备方法
JP2023553117A5 (enExample)
CA3212362A1 (en) Ezrin peptide 1 for use in a method of treating post covid-19
JP2014510126A5 (ja) Ｉｆｎアルファ関連疾病の処置方法
EP4159233A1 (en) Pharmaceutical composition comprising polynucleotides and use thereof for prevention or treatment of covid-19
CN115925823A (zh) SARS-CoV-2编码蛋白来源的T细胞表位多肽FAFPFTIYSL及其应用
EP0351876A2 (en) Composition for potentiating vaccination effect
WO2021198346A2 (en) Ezrin peptide 1 for use in a method of treating covid-19
CN112386688B (zh) 一种用于病毒治疗的含有免疫细胞的药物组合物
Li Advances in the study of cytokine storm mechanisms in pneumonia: an example of IL-6 and IL-33
ES2736503T3 (es) Nuevos análogos de la proteína IFN beta
Assi et al. Investigational immunomodulatory therapies for COVID-19
US20060257364A1 (en) Materials and methods for inhibition of IgE production
Mohammed et al. Therapeutic challenges of COVID-19: strategies of empirical treatment
RU2017126043A (ru) Композиция от бешенства, содержащая адъювант pika
KR101736870B1 (ko) 인터페론 접합체를 포함하는 복합체 및 이의 제조방법